Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases
Clinical Psychopharmacology and Neuroscience
; : 174-178, 2021.
Article
em En
| WPRIM
| ID: wpr-874480
Biblioteca responsável:
WPRO
ABSTRACT
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D2 /D3 receptors with preferential binding to the D 3 receptor, antagonism of 5HT2B receptors, and partial agonism of 5HT1A . Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.
Texto completo:
1
Índice:
WPRIM
Idioma:
En
Revista:
Clinical Psychopharmacology and Neuroscience
Ano de publicação:
2021
Tipo de documento:
Article